Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00180869 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Unmodified Versus Leuko-reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study description revisedv2 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There is evidence to suggest that red blood cell concentrate (RBC) transfusion may have immunomodulatory effects. The aim of this randomized single-center trial is to compare immune responses in patients undergoing cancer surgery and given either an unmodified RBC (UN-RBC) or a leuko-reduced RBC (LR-RBC) transfusion perioperatively.
Trial Details
NCT Number NCT00180869
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Cancer, Surgery
Enrollment 150 participants
Start Date
Updated on ClinicalTrials.gov